Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales
Tablas, estadísticas.
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2024
- Institución:
- Universidad de Caldas
- Repositorio:
- Repositorio Institucional U. Caldas
- Idioma:
- eng
spa
- OAI Identifier:
- oai:repositorio.ucaldas.edu.co:ucaldas/19876
- Acceso en línea:
- https://repositorio.ucaldas.edu.co/handle/ucaldas/19876
- Palabra clave:
- COVID-19
Trombosis
Embolismo pulmonar
Tromboprofilaxis
Medicina de Urgencias
- Rights
- openAccess
- License
- http://purl.org/coar/access_right/c_abf2
| id |
REPOUCALDA_ebe71283b9da2a416beaa2d7f60fb14e |
|---|---|
| oai_identifier_str |
oai:repositorio.ucaldas.edu.co:ucaldas/19876 |
| network_acronym_str |
REPOUCALDA |
| network_name_str |
Repositorio Institucional U. Caldas |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales |
| title |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales |
| spellingShingle |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales COVID-19 Trombosis Embolismo pulmonar Tromboprofilaxis Medicina de Urgencias |
| title_short |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales |
| title_full |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales |
| title_fullStr |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales |
| title_full_unstemmed |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales |
| title_sort |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizales |
| dc.contributor.none.fl_str_mv |
Jimenez Benavidez, Santiago |
| dc.subject.none.fl_str_mv |
COVID-19 Trombosis Embolismo pulmonar Tromboprofilaxis Medicina de Urgencias |
| topic |
COVID-19 Trombosis Embolismo pulmonar Tromboprofilaxis Medicina de Urgencias |
| description |
Tablas, estadísticas. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024-04-30T15:30:52Z 2024-04-30T15:30:52Z 2024-04-30 |
| dc.type.none.fl_str_mv |
Trabajo de grado - Especialización http://purl.org/coar/resource_type/c_18ws Text info:eu-repo/semantics/masterThesis |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.identifier.none.fl_str_mv |
https://repositorio.ucaldas.edu.co/handle/ucaldas/19876 Universidad de Caldas Repositorio Institucional Universidad de Caldas repositorio.ucaldas.edu.co |
| url |
https://repositorio.ucaldas.edu.co/handle/ucaldas/19876 |
| identifier_str_mv |
Universidad de Caldas Repositorio Institucional Universidad de Caldas repositorio.ucaldas.edu.co |
| dc.language.none.fl_str_mv |
eng spa |
| language |
eng spa |
| dc.relation.none.fl_str_mv |
Stavros DT, Konstantinides V, Grecia A, Espan B, Meyer G, Italia CB, et al. Guía de práctica clínica para El Diagnostico Y Tratamiento De La Embolia Pulmonar. Rev Esp Cardiol. 2020;73(6):1–46. De Miguel-Diez J, Jiménez-Garcia R, Jiménez D, Monreal M, Guijarro R, Otero R, et al. Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. Eur Respir J. 2014;44(4):942–50. Aylin P, Bottle A, Kirkwood G, Bell D. Trends in hospital admissions for pulmonary embolism in England: 1996/7 to 2005/6. Clin Med J R Coll Physicians London. 2008;8(4):388–92. Shiraev TP, Omari A, Rushworth RL. Trends in pulmonary embolism morbidity and mortality in Australia. Thromb Res [Internet]. 2013;132(1):19–25. Available from: http://dx.doi.org/10.1016/j.thromres.2013.04.032 Dennis RJ, Rojas MX, Molina Á, Roa J, Granados M, Londoño A, et al. Curso clínico y supervivencia en embolia pulmonar. Resultados del registro multicéntrico colombiano (EMEPCO). Acta Medica Colomb. 2008;33(3):111–6. David J, Sandoval G, David J, Sandoval G, Cauca U, Karolina D, et al. Comportamiento de la enfermedad tromboembólica venosa en un centro hospitalario de la ciudad de Popayán, Colombia. 2021;11(digita l):1–18. Pachon Grajales I, Agudelo Restrepo CA, Uribe Molano J david, Agudelos Zuluaga MM, Agudelo Zuluaga ID, Carvajal Lopez MA, et al. Pacientes con tromboembolismo pulmonar: caracterizacion. Med UPB. 2006;25(1):83–92. Rashidi F, Barco S, Kamangar F, Heresi GA, Emadi A, Kaymaz C, et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. Thromb Res [Internet]. 2021;198(September 2020):135–8. https://doi.org/10.1016/j.thromres.2020.12.001 Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc Med (United Kingdom). 2021;26(4):415–25 Mai V, Kim B, Mainbourg S, Potus F, Cucherat M. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with metaanalysis. 2020;(January). Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377:e069590. Korompoki E, Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. Am J Hematol. 2022;97(1):119–28. Fraser E. Long term respiratory complications of covid-19. BMJ. 2020;370:m3001. Rodriguez-guerra M, Jadhav P, Vittorio TJ. Current treatment in COVID-19 disease: a rapid review. Drugs Context. 2021;10:1–8. Gonzalez-fajardo JA, Ansuategui M, Romero C, Comanges A. Mortalidad de los pacientes covid-19 con complicaciones trombóticas. 2020;(January). Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J, Rea C, et al. Postdischarge venous thromboembolism following hospital admission with COVID19. Blood. 2020;136(11):1347–50. Ron Gilat, M.D., Eric D. Haunschild B.S., Tracy Tauro B.S. B.A., Brian J. Cole M.D. MB. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019 CHEST Guideline and Expert Panel Report. Ann Oncol. 2020;(January):19–21. Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–65. Correa-perez LP. Incidencia de eventos tromboembólicos venosos en pacientes hospitalizados con COVID-19. Acta Colomb Cuid Intensivo [Internet]. 2020;22(xx). Available from: https://doi.org/10.1016/j.acci.2020.11.003 Saavedra Trujillo CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Infectio. 2020;24(3):1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol [Internet]. 2019;17(3):181–92. http://dx.doi.org/10.1038/s41579-018-0118-9 Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev [Internet]. 2021;19(3):141–54. http://dx.doi.org/10.1038/s41579-020-00459-7 Jordan RE, Adab P, Cheng KK. Covid-19: Risk factors for severe disease and death. BMJ [Internet]. 2020;368(March):1–2. http://dx.doi.org/doi:10.1136/bmj.m1198 Yang J, Zheng Y, Gou X, Pu K, Chen Z. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis [Internet]. 2020;94(March):91–5. https://pubmed.ncbi.nlm.nih.gov/32173574/ Wang J, Cheng J, Shao H. Clinical Findings of Patients with Coronavirus Disease 2019 in Jiangsu Province, China: A Retrospective, Multi-Center Study. 2019. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. Jama. 2020;323(14):1335. Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, et al. Diagnostics for SARS-CoV-2 infections. Nat Mater [Internet]. 2021;20(5):593–605. Available from: http://dx.doi.org/10.1038/s41563-020-00906-z Rubin GD. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiol RSNA. 2019;1–24. Garcia M, Calvo M. Manejo clínico de pacientes con enfermedad por el nuevo coronavirus (COVID-19). 2020;1–36. Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Venous thromboembolism in COVID-19: Systematic review of reported risks and current guidelines. Swiss Med Wkly. 2020;150(25–26). Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. Pontone G, Scafuri S, Elisabetta M, Agalbato C, Guglielmo M, Baggiano A, et al. Role of computed tomography in COVID-19. 2020;(January). López-Reyes R, Oscullo G, Jiménez D, Cano I, García-Ortega A. Riesgo trombótico y COVID-19: revisión de la evidencia actual para una mejor aproximación diagnóstica y terapéutica. Arch Bronconeumol. 2021;57(Dd):55–64. Abou-ismail MY, Diamond A, Kapoor S, Arafah Y. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. 2020;(January). Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–4. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–40. Zhou F. Clinical Course And Risk Factors For Mortality Of Adult In Patients With COVID-19 In Wuhan, China: A Retrospective Cohort Study. J Med Study Res. 2020;3(1):01–2. Ullah W, Saeed R, Sarwar U, Patel R, Fischman DL. COVID-19 Complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure. JACC Case Reports [Internet]. 2020;2(9):1379–82. https://doi.org/10.1016/j.jaccas.2020.04.008 Rosen RJ. Thrombotic complications in critically ill patients with COVID 19. Thromb Res. 2020;191(January):56. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743–6 Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J, Maillet JM, et al. Venous Thrombosis among Critically Ill Patients with Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020;3(5):2020–3. Jiménez D, García-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest. 2021;159(3):118296. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine [Internet]. 2020;29–30:100639. Available from: https://doi.org/10.1016/j.eclinm.2020.100639 Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary Embolism in Patients with COVID-19: Awareness of an Increased Prevalence. Circulation. 2020;142(2):184–6. Rieder M, Goller I, Jeserich M, Baldus N, Pollmeier L, Wirth L, et al. Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19. J Thromb Thrombolysis [Internet]. 2020;50(3):558–66. https://doi.org/10.1007/s11239-020-02202-8 Roubinian NH, Dusendang JR, Mark DG, Vinson DR, Liu VX, Schmittdiel JA, et al. Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California. JAMA Intern Med. 2021;181(7):997–1000. Salisbury R, Iotchkova V, Jaafar S, Morton J, Sangha G, Shah A, et al. Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Adv. 2020;4(24):6230–9. Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, Hadi HA, et al. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front Immunol. 2021;12(February):1–23. Sonja A et al. Emergencia de SARS-CoV-2. Aspectos básicos sobre su origen, epidemiología, estructura y patogenia para clínicos. Ann Oncol. 2020;(January):1921. Gutierrez Choque BJ, Aruquipa Quispe CJ. Covid-19: Aspectos virológicos y patogénesis. Rev Cient Cienc Medica. 2020;23(1):77–86. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270–84. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:1–6. Covid- F, Manta B, Sarkisian AG. Fisiopatología de la enfermedad COVID-19. Odontoestomatologia. 2022;24:1–19. Lopes-Pacheco M, Silva PL, Cruz FF, Battaglini D, Robba C, Pelosi P, et al. Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Front Physiol. 2021;12(January):1–23. Dawood FS, Ricks P, Njie GJ, Daugherty M, Davis W, Fuller JA, et al. Observations of the global epidemiology of COVID-19 from the prepandemic period using webbased surveillance: a cross-sectional analysis. Lancet Infect Dis [Internet]. 2020;20(11):1255–62. Available 3099(20)30581-8 Reporte de situación COVID-19 Colombia No. 293 - 8 de marzo 2023. Paho.org. Recuperado el 1 de abril de 2024, de https://www.paho.org/es/documentos/reportesituacion-covid-19-colombia-no-293-8-marzo-2023. World Health Organization. Definición de casos de COVID-19 utilizada por la OMS. Vigil salud pública en relación con la COVID-19orientaciones provisionales, 7 agosto 2020 [Internet]. 2020;12. nCoV/Surveillance_Case_Definition/2020.1 Ministerio de Salud y Protección Social Bogotá. Lineamientos base para la formulación de definiciones de caso en vigilancia en Salud Pública. Aplicación en COVID-19. MinSalud. 2020;1–39. World Health Organization. Pruebas diagnósticas para el SARS-CoV-2. World Heal Organ [Internet]. 2020;26. Available https://apps.who.int/iris/bitstream/handle/10665/335830/WHO-2019-nCoVlaboratory-2020.6-spa.pdf Ministerio de Salud. Lineamientos para el uso de pruebas diagnósticas de SARSCov-2 (COVID-19) en Colombia. Ministerio. 2022;10:1–21. Heit JA. The epidemiology of venous thromboembolism in the community: Implications for prevention and management. Vein B. 2007;28(3):323–30. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, et al. Diagnosis and management of acute deep vein thrombosis: A joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39(47):4208–18. Stavros DT, Konstantinides V, Grecia A, Espan B, Meyer G, Italia CB, et al. Guía ESC 2019 Para El Diagnostico Y Tratamiento De La Embolia Pulmonar. Rev Esp Cardiol. 2020;73(6):1–46. Emeka Kesieme, Chinenye Kesieme, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: a clinical review. J Blood Med. 2011;59. Hobohm L, Lankeit M. Pulmonary Embolism. Pneumologie. 2021;75(10):800–18. Howard L. Acute pulmonary embolism. Clin Med J R Coll Physicians London. 2019;19(3):243–7. Toori KU, Qureshi MA, Chaudhry A, Safdar MF. Neutrophil to lymphocyte ratio (NLR) in COVID-19: A cheap prognostic marker in a resource constraint setting. Pak J Med Sci. 2021 Sep-Oct;37(5):1435-1439. doi: 10.12669/pjms.37.5.4194. PMID: 34475926; PMCID: PMC8377926. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30. doi: 10.1016/j.critrevonc.2013.03.010. Epub 2013 Apr 17. PMID: 23602134. Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S, Gobunsuy R, Jadonath S, Baldari D, McCord D, Lafferty J. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010 Aug 15;106(4):470-6. doi: 10.1016/j.amjcard.2010.03.062. PMID: 20691303. Liu X, Shen Y, Wang H, Ge Q, Fei A, Pan S. Prognostic Significance of Neutrophil-toLymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study. Mediators Inflamm. 2016;2016:8191254. doi: 10.1155/2016/8191254. Epub 2016 Mar 24. PMID: 27110067; PMCID: PMC4823514. Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, Bauer KA, Zwicker JI. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020 Sep 10;136(11):1342-1346. doi: 10.1182/blood.2020007938. PMID: 32766883; PMCID: PMC7483433. Bourguignon A, Beaulieu C, Belkaid W, Desilets A, Blais N. Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection. Thromb Res. 2020 Dec;196:491-493. doi: 10.1016/j.thromres.2020.10.017. Epub 2020 Oct 15. PMID: 33091702; PMCID: PMC7557256. Petrova D, Salamanca-Fernández E, Rodríguez Barranco M, Navarro Pérez P, Jiménez Moleón JJ, Sánchez MJ. La obesidad como factor de riesgo en personas con COVID-19: posibles mecanismos e implicaciones [Obesity as a risk factor in COVID19: Possible mechanisms and implications]. Aten Primaria. 2020 AugSep;52(7):496-500. Spanish. doi: 10.1016/j.aprim.2020.05.003. Epub 2020 May 25. PMID: 32586628; PMCID: PMC7247450. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M; LICORN and the Lille COVID-19 and Obesity study group. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 2020 Jul;28(7):1195-1199. doi: 10.1002/oby.22831. Epub 2020 Jun 10. Erratum in: Obesity (Silver Spring). 2020 Oct;28(10):1994. PMID: 32271993; PMCID: PMC7262326. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966. doi: 10.1136/bmj.m1966. PMID: 32444366; PMCID: PMC7243801. Castro-Arellano SB, Sandoval-Mosqueda LE, Flores-Murrieta FJ. Índice de saturación y fracción inspirada de oxígeno en COVID-19 [Saturation index and fraction of inspired oxygen as a predictor in COVID-19]. Rev Med Inst Mex Seguro Soc. 2023 Oct 2;61(Suppl 3):S416-S421. Spanish. doi: 10.5281/zenodo.8319752. PMID: 37934832; PMCID: PMC10735272. Lu X, Jiang L, Chen T, Wang Y, Zhang B, Hong Y, Wang J, Yan F. Continuously available ratio of SpO2/FiO2 serves as a noninvasive prognostic marker for intensive care patients with COVID-19. Respir Res. 2020 Jul 22;21(1):194. doi: 10.1186/s12931-020-01455-4. PMID: 32698822; PMCID: PMC7374662. Lehmann A, Prosch H, Zehetmayer S, Gysan MR, Bernitzky D, Vonbank K, Idzko M, Gompelmann D. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS One. 2021 Oct 28;16(10):e0258351. 10.1371/journal.pone.0258351. PMID: 34710097; PMCID: PMC8553152. Fialek B, Pruc M, Smereka J, Jas R, Rahnama-Hezavah M, Denegri A, Szarpak A, Jaguszewski MJ, Peacock FW, Szarpak L. Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis. Cardiol J. 2022;29(5):751-758. doi: 10.5603/CJ.a2022.0056. Epub 2022 Jun 28. PMID: 35762075; PMCID: PMC9550334. |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess info:eu-repo/semantics/openAccess info:eu-repo/semantics/openAccess info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Facultad de Ciencias para la Salud Manizales Especialización en Medicina De Urgencias |
| publisher.none.fl_str_mv |
Facultad de Ciencias para la Salud Manizales Especialización en Medicina De Urgencias |
| institution |
Universidad de Caldas |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1836145006595801088 |
| spelling |
Frecuencia de enfermedad tromboembólica venosa en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en una institución de tercer nivel de la ciudad de manizalesCOVID-19TrombosisEmbolismo pulmonarTromboprofilaxisMedicina de UrgenciasTablas, estadísticas.spa: La COVID-19 es una infección respiratoria aguda causada por el coronavirus SARS-CoV2, que se propagó de manera exponencial a nivel mundial, lo que convirtió esta situación en una emergencia sanitaria de preocupación internacional. La coagulopatía inducida por la COVID-19 se presenta secundario a una respuesta inflamatoria sistémica exagerada, que con frecuencia termina en cuadros clínicos de enfermedad tromboembólica (ETEV). Actualmente no está claro el uso de tromboprofilaxis extendida después de la infección debido a la escasez de datos que informen sobre la incidencia de tromboembolismo venoso. Por esta razón, el presente estudio pretende evaluar la frecuencia de ETEV en los 3 meses siguientes al alta hospitalaria por COVID-19 no severo en un hospital de III nivel de complejidad de la ciudad de Manizales. Se realizó un estudio observacional, descriptivo de una cohorte retrospectiva que incluyó pacientes con diagnóstico de COVID-19 no severo que consultaron al servicio de urgencias dentro de los 3 meses posteriores al alta hospitalaria con síntomas sugestivos de TEV, en los que se confirmó embolismo pulmonar (EP) y/o trombosis venosa profunda (TVP) por imágenes. La frecuencia de ETEV venosa fue del 1.8%. Del total de pacientes, 13 (81.25%) tuvieron EP, 2 (12.5%) tuvieron TVP y 1 (6.25%) tuvo ambas. Con este estudio se puede inferir que el riesgo tromboembólico en pacientes dados de alta con COVID-19 no severo es bajo. Se recomiendan ensayos clínicos y/o estudios de naturaleza prospectiva que respalden el uso de esta terapia en este contexto clínico.eng: COVID-19 is an acute respiratory infection caused by the SARS-CoV2 coronavirus, which spread exponentially worldwide, turning this situation into a health emergency of international concern. COVID-19-induced coagulopathy occurs secondary to an exaggerated systemic inflammatory response, which frequently ends in clinical symptoms of thromboembolic disease (VTE). The use of extended thromboprophylaxis after infection is currently 5eep5lo due to the paucity of data reporting the incidence of venous thromboembolism. For this reason, the present study aims to evaluate the frequency of VTE in the 3 months following hospital discharge for non-severe COVID-19 in a III 5eep5lof complexity hospital in the city of Manizales. An observational, descriptive study was carried out on a retrospective cohort that included patients with a diagnosis of non-severe COVID 19 who consulted the emergency department within 3 months after hospital discharge with symptoms suggestive of VTE, in which pulmonary embolism was confirmed. (PE) and/or 5eep vein thrombosis (DVT) by imaging. The frequency of venous VTE was 1.8%. Of the total patients, 13 (81.25%) had PE, 2 (12.5%) had DVT and 1 (6.25%) had both. With this study, it can be inferred that the thromboembolic risk in patients discharged with non-severe COVID-19 is low. Clinical trials and/or studies of a prospective nature are recommended to support the use of this therapy in this clinical context.Planteamiento del problema /Antecedentes de investigación /Pregunta de investigación / Justificación /Consideraciones éticas / Marco teórico/Infección por el virus SARS-CoV2 /Enfermedad tromboembólica venosa/Objetivo general /Objetivos específicos/Metodología /Tipo y diseño del estudio / Población/Criterios de inclusión/Criterios de exclusión/ Operacionalización de variables/ Recolección de la información /Cronograma /Presupuesto /Resultados /Discusión /Limitaciones /Conclusiones/Anexos /Referencias bibliográficasEspecializaciónEspecialista en Medicina De UrgenciasFacultad de Ciencias para la SaludManizalesEspecialización en Medicina De UrgenciasJimenez Benavidez, SantiagoTrujillo López, Catalina2024-04-30T15:30:52Z2024-04-30T15:30:52Z2024-04-30Trabajo de grado - Especializaciónhttp://purl.org/coar/resource_type/c_18wsTextinfo:eu-repo/semantics/masterThesishttp://purl.org/coar/version/c_970fb48d4fbd8a85application/pdfapplication/pdfapplication/pdfapplication/pdfhttps://repositorio.ucaldas.edu.co/handle/ucaldas/19876Universidad de CaldasRepositorio Institucional Universidad de Caldasrepositorio.ucaldas.edu.coengspaStavros DT, Konstantinides V, Grecia A, Espan B, Meyer G, Italia CB, et al. Guía de práctica clínica para El Diagnostico Y Tratamiento De La Embolia Pulmonar. Rev Esp Cardiol. 2020;73(6):1–46.De Miguel-Diez J, Jiménez-Garcia R, Jiménez D, Monreal M, Guijarro R, Otero R, et al. Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. Eur Respir J. 2014;44(4):942–50.Aylin P, Bottle A, Kirkwood G, Bell D. Trends in hospital admissions for pulmonary embolism in England: 1996/7 to 2005/6. Clin Med J R Coll Physicians London. 2008;8(4):388–92.Shiraev TP, Omari A, Rushworth RL. Trends in pulmonary embolism morbidity and mortality in Australia. Thromb Res [Internet]. 2013;132(1):19–25. Available from: http://dx.doi.org/10.1016/j.thromres.2013.04.032Dennis RJ, Rojas MX, Molina Á, Roa J, Granados M, Londoño A, et al. Curso clínico y supervivencia en embolia pulmonar. Resultados del registro multicéntrico colombiano (EMEPCO). Acta Medica Colomb. 2008;33(3):111–6.David J, Sandoval G, David J, Sandoval G, Cauca U, Karolina D, et al. Comportamiento de la enfermedad tromboembólica venosa en un centro hospitalario de la ciudad de Popayán, Colombia. 2021;11(digita l):1–18.Pachon Grajales I, Agudelo Restrepo CA, Uribe Molano J david, Agudelos Zuluaga MM, Agudelo Zuluaga ID, Carvajal Lopez MA, et al. Pacientes con tromboembolismo pulmonar: caracterizacion. Med UPB. 2006;25(1):83–92.Rashidi F, Barco S, Kamangar F, Heresi GA, Emadi A, Kaymaz C, et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. Thromb Res [Internet]. 2021;198(September 2020):135–8. https://doi.org/10.1016/j.thromres.2020.12.001Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc Med (United Kingdom). 2021;26(4):415–25Mai V, Kim B, Mainbourg S, Potus F, Cucherat M. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with metaanalysis. 2020;(January).Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377:e069590.Korompoki E, Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. Am J Hematol. 2022;97(1):119–28.Fraser E. Long term respiratory complications of covid-19. BMJ. 2020;370:m3001.Rodriguez-guerra M, Jadhav P, Vittorio TJ. Current treatment in COVID-19 disease: a rapid review. Drugs Context. 2021;10:1–8.Gonzalez-fajardo JA, Ansuategui M, Romero C, Comanges A. Mortalidad de los pacientes covid-19 con complicaciones trombóticas. 2020;(January).Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J, Rea C, et al. Postdischarge venous thromboembolism following hospital admission with COVID19. Blood. 2020;136(11):1347–50.Ron Gilat, M.D., Eric D. Haunschild B.S., Tracy Tauro B.S. B.A., Brian J. Cole M.D. MB. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019 CHEST Guideline and Expert Panel Report. Ann Oncol. 2020;(January):19–21.Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–65.Correa-perez LP. Incidencia de eventos tromboembólicos venosos en pacientes hospitalizados con COVID-19. Acta Colomb Cuid Intensivo [Internet]. 2020;22(xx). Available from: https://doi.org/10.1016/j.acci.2020.11.003Saavedra Trujillo CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Infectio. 2020;24(3):1.Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol [Internet]. 2019;17(3):181–92. http://dx.doi.org/10.1038/s41579-018-0118-9Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev [Internet]. 2021;19(3):141–54. http://dx.doi.org/10.1038/s41579-020-00459-7Jordan RE, Adab P, Cheng KK. Covid-19: Risk factors for severe disease and death. BMJ [Internet]. 2020;368(March):1–2. http://dx.doi.org/doi:10.1136/bmj.m1198Yang J, Zheng Y, Gou X, Pu K, Chen Z. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis [Internet]. 2020;94(March):91–5. https://pubmed.ncbi.nlm.nih.gov/32173574/Wang J, Cheng J, Shao H. Clinical Findings of Patients with Coronavirus Disease 2019 in Jiangsu Province, China: A Retrospective, Multi-Center Study. 2019.Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. Jama. 2020;323(14):1335.Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, et al. Diagnostics for SARS-CoV-2 infections. Nat Mater [Internet]. 2021;20(5):593–605. Available from: http://dx.doi.org/10.1038/s41563-020-00906-zRubin GD. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiol RSNA. 2019;1–24.Garcia M, Calvo M. Manejo clínico de pacientes con enfermedad por el nuevo coronavirus (COVID-19). 2020;1–36.Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Venous thromboembolism in COVID-19: Systematic review of reported risks and current guidelines. Swiss Med Wkly. 2020;150(25–26).Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704.Pontone G, Scafuri S, Elisabetta M, Agalbato C, Guglielmo M, Baggiano A, et al. Role of computed tomography in COVID-19. 2020;(January).López-Reyes R, Oscullo G, Jiménez D, Cano I, García-Ortega A. Riesgo trombótico y COVID-19: revisión de la evidencia actual para una mejor aproximación diagnóstica y terapéutica. Arch Bronconeumol. 2021;57(Dd):55–64.Abou-ismail MY, Diamond A, Kapoor S, Arafah Y. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. 2020;(January).Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–4.Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–40.Zhou F. Clinical Course And Risk Factors For Mortality Of Adult In Patients With COVID-19 In Wuhan, China: A Retrospective Cohort Study. J Med Study Res. 2020;3(1):01–2.Ullah W, Saeed R, Sarwar U, Patel R, Fischman DL. COVID-19 Complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure. JACC Case Reports [Internet]. 2020;2(9):1379–82. https://doi.org/10.1016/j.jaccas.2020.04.008Rosen RJ. Thrombotic complications in critically ill patients with COVID 19. Thromb Res. 2020;191(January):56.Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743–6Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J, Maillet JM, et al. Venous Thrombosis among Critically Ill Patients with Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020;3(5):2020–3.Jiménez D, García-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest. 2021;159(3):118296.Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine [Internet]. 2020;29–30:100639. Available from: https://doi.org/10.1016/j.eclinm.2020.100639Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary Embolism in Patients with COVID-19: Awareness of an Increased Prevalence. Circulation. 2020;142(2):184–6.Rieder M, Goller I, Jeserich M, Baldus N, Pollmeier L, Wirth L, et al. Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19. J Thromb Thrombolysis [Internet]. 2020;50(3):558–66. https://doi.org/10.1007/s11239-020-02202-8Roubinian NH, Dusendang JR, Mark DG, Vinson DR, Liu VX, Schmittdiel JA, et al. Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California. JAMA Intern Med. 2021;181(7):997–1000.Salisbury R, Iotchkova V, Jaafar S, Morton J, Sangha G, Shah A, et al. Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Adv. 2020;4(24):6230–9.Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, Hadi HA, et al. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front Immunol. 2021;12(February):1–23.Sonja A et al. Emergencia de SARS-CoV-2. Aspectos básicos sobre su origen, epidemiología, estructura y patogenia para clínicos. Ann Oncol. 2020;(January):1921.Gutierrez Choque BJ, Aruquipa Quispe CJ. Covid-19: Aspectos virológicos y patogénesis. Rev Cient Cienc Medica. 2020;23(1):77–86.Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270–84.Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:1–6.Covid- F, Manta B, Sarkisian AG. Fisiopatología de la enfermedad COVID-19. Odontoestomatologia. 2022;24:1–19.Lopes-Pacheco M, Silva PL, Cruz FF, Battaglini D, Robba C, Pelosi P, et al. Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Front Physiol. 2021;12(January):1–23.Dawood FS, Ricks P, Njie GJ, Daugherty M, Davis W, Fuller JA, et al. Observations of the global epidemiology of COVID-19 from the prepandemic period using webbased surveillance: a cross-sectional analysis. Lancet Infect Dis [Internet]. 2020;20(11):1255–62. Available 3099(20)30581-8Reporte de situación COVID-19 Colombia No. 293 - 8 de marzo 2023. Paho.org. Recuperado el 1 de abril de 2024, de https://www.paho.org/es/documentos/reportesituacion-covid-19-colombia-no-293-8-marzo-2023.World Health Organization. Definición de casos de COVID-19 utilizada por la OMS. Vigil salud pública en relación con la COVID-19orientaciones provisionales, 7 agosto 2020 [Internet]. 2020;12. nCoV/Surveillance_Case_Definition/2020.1Ministerio de Salud y Protección Social Bogotá. Lineamientos base para la formulación de definiciones de caso en vigilancia en Salud Pública. Aplicación en COVID-19. MinSalud. 2020;1–39.World Health Organization. Pruebas diagnósticas para el SARS-CoV-2. World Heal Organ [Internet]. 2020;26. Available https://apps.who.int/iris/bitstream/handle/10665/335830/WHO-2019-nCoVlaboratory-2020.6-spa.pdfMinisterio de Salud. Lineamientos para el uso de pruebas diagnósticas de SARSCov-2 (COVID-19) en Colombia. Ministerio. 2022;10:1–21.Heit JA. The epidemiology of venous thromboembolism in the community: Implications for prevention and management. Vein B. 2007;28(3):323–30.Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, et al. Diagnosis and management of acute deep vein thrombosis: A joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39(47):4208–18.Stavros DT, Konstantinides V, Grecia A, Espan B, Meyer G, Italia CB, et al. Guía ESC 2019 Para El Diagnostico Y Tratamiento De La Embolia Pulmonar. Rev Esp Cardiol. 2020;73(6):1–46.Emeka Kesieme, Chinenye Kesieme, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: a clinical review. J Blood Med. 2011;59.Hobohm L, Lankeit M. Pulmonary Embolism. Pneumologie. 2021;75(10):800–18.Howard L. Acute pulmonary embolism. Clin Med J R Coll Physicians London. 2019;19(3):243–7.Toori KU, Qureshi MA, Chaudhry A, Safdar MF. Neutrophil to lymphocyte ratio (NLR) in COVID-19: A cheap prognostic marker in a resource constraint setting. Pak J Med Sci. 2021 Sep-Oct;37(5):1435-1439. doi: 10.12669/pjms.37.5.4194. PMID: 34475926; PMCID: PMC8377926.Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30. doi: 10.1016/j.critrevonc.2013.03.010. Epub 2013 Apr 17. PMID: 23602134.Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S, Gobunsuy R, Jadonath S, Baldari D, McCord D, Lafferty J. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010 Aug 15;106(4):470-6. doi: 10.1016/j.amjcard.2010.03.062. PMID: 20691303.Liu X, Shen Y, Wang H, Ge Q, Fei A, Pan S. Prognostic Significance of Neutrophil-toLymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study. Mediators Inflamm. 2016;2016:8191254. doi: 10.1155/2016/8191254. Epub 2016 Mar 24. PMID: 27110067; PMCID: PMC4823514.Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, Bauer KA, Zwicker JI. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020 Sep 10;136(11):1342-1346. doi: 10.1182/blood.2020007938. PMID: 32766883; PMCID: PMC7483433.Bourguignon A, Beaulieu C, Belkaid W, Desilets A, Blais N. Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection. Thromb Res. 2020 Dec;196:491-493. doi: 10.1016/j.thromres.2020.10.017. Epub 2020 Oct 15. PMID: 33091702; PMCID: PMC7557256.Petrova D, Salamanca-Fernández E, Rodríguez Barranco M, Navarro Pérez P, Jiménez Moleón JJ, Sánchez MJ. La obesidad como factor de riesgo en personas con COVID-19: posibles mecanismos e implicaciones [Obesity as a risk factor in COVID19: Possible mechanisms and implications]. Aten Primaria. 2020 AugSep;52(7):496-500. Spanish. doi: 10.1016/j.aprim.2020.05.003. Epub 2020 May 25. PMID: 32586628; PMCID: PMC7247450.Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M; LICORN and the Lille COVID-19 and Obesity study group. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 2020 Jul;28(7):1195-1199. doi: 10.1002/oby.22831. Epub 2020 Jun 10. Erratum in: Obesity (Silver Spring). 2020 Oct;28(10):1994. PMID: 32271993; PMCID: PMC7262326.Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966. doi: 10.1136/bmj.m1966. PMID: 32444366; PMCID: PMC7243801.Castro-Arellano SB, Sandoval-Mosqueda LE, Flores-Murrieta FJ. Índice de saturación y fracción inspirada de oxígeno en COVID-19 [Saturation index and fraction of inspired oxygen as a predictor in COVID-19]. Rev Med Inst Mex Seguro Soc. 2023 Oct 2;61(Suppl 3):S416-S421. Spanish. doi: 10.5281/zenodo.8319752. PMID: 37934832; PMCID: PMC10735272.Lu X, Jiang L, Chen T, Wang Y, Zhang B, Hong Y, Wang J, Yan F. Continuously available ratio of SpO2/FiO2 serves as a noninvasive prognostic marker for intensive care patients with COVID-19. Respir Res. 2020 Jul 22;21(1):194. doi: 10.1186/s12931-020-01455-4. PMID: 32698822; PMCID: PMC7374662.Lehmann A, Prosch H, Zehetmayer S, Gysan MR, Bernitzky D, Vonbank K, Idzko M, Gompelmann D. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS One. 2021 Oct 28;16(10):e0258351. 10.1371/journal.pone.0258351. PMID: 34710097; PMCID: PMC8553152.Fialek B, Pruc M, Smereka J, Jas R, Rahnama-Hezavah M, Denegri A, Szarpak A, Jaguszewski MJ, Peacock FW, Szarpak L. Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis. Cardiol J. 2022;29(5):751-758. doi: 10.5603/CJ.a2022.0056. Epub 2022 Jun 28. PMID: 35762075; PMCID: PMC9550334.info:eu-repo/semantics/openAccessinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2oai:repositorio.ucaldas.edu.co:ucaldas/198762024-07-16T21:39:00Z |